Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nose V, Mete O. Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol. 2021;32(3):327-335.

Larose H, Prokoph N, Matthews JD, Schlederer M, Högler S, Alsulami AF, et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2021;106(6):1693-1704.

Hwang I, Tang D, Paik J. Oxidative stress sensing and response in neural stem cell fate. Free Radic Biol Med. 2021;169:74-83.

Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).

Mueller AC, Piper M, Goodspeed A, Bhuvane S, Williams JS, Bhatia S, et al. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Cancer Res. 2021;81(12):3255-3269.

Chen J, Tomasek M, Cruz A, Faron ML, Liu D, Rodgers WH, et al. Feasibility and potential significance of rapid in vitro qualitative phenotypic antimicrobial susceptibility testing of gram-negative bacilli with the ProMax system. PLoS One. 2021;16(3):e0249203.

Willcockson MA, Healton SE, Weiss CN, Bartholdy BA, Botbol Y, Mishra LN, et al. H1 histones control the epigenetic landscape by local chromatin compaction. Nature. 2021;589(7841):293-298.

Sakunrangsit N, Pholtaisong J, Sucharitakul J, Wanna-Udom S, Prombutara P, Pisitkun P, et al. Identification of candidate regulators of mandibular bone loss in FcγRIIB Mice. Sci Rep. 2021;11(1):18726.

Di Lorenzo A. Sphingosine-1-phosphate receptor-1 (S1PR1) signalling: the homeostatic pathway of the heart. Cardiovasc Res. 2021;117(2):357-359.

Petroni G, Buqué A, Yamazaki T, Bloy N, Di Liberto M, Chen-Kiang S, et al. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. Clin Cancer Res. 2021;27(7):1855-1863.